Pharmaceutical company AgeneBio recently announced the publication of results of a Phase 2 clinical trial based on the company’s therapeutic product AGB101 for the pre-dementia stage of Alzheimer’s disease in the journal NeuroImage: Clinical. The study entitled “Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task…
A drug commonly used to treat epilepsy could help “slow down” the progress of Alzheimer’s disease, reports The Daily Express. According to the news story, the drug levetiracetam was shown to “help restore brain function and memory”. The story is based on a study analysing the short-term effect of the drug in 54 people with…
Trying to translate discovery research and early clinical data into phase III success has proved the bane for drug developers working in Alzheimer’s disease. But executives at Agenebio Inc., which is gearing up to start a phase III study in the second half of this year with lead product AGB101, think their approach will be…
Researchers at John Hopkins University have found that low doses of a drug more commonly used to treat epilepsy can reverse a condition that increases the risk of developing Alzheimer’s disease…
A common epilepsy drug may reverse a condition that impairs memory in elderly patients and increases the risk of developing Alzheimer’s disease, suggests a study published this week in the journal NeuroImage: Clinical…
A new drug approach helped restore the memory of elderly patients who are at high risk for dementia due to Alzheimer’s, and may potentially delay the onset of this debilitating disease, according to new research.
Recent data published by the National Institutes on Aging show that modest delays in the onset of Alzheimer’s related dementia have massive benefits to patients, their families and society as a whole, the CEO of a company creating a new drug for the disease told BioSpace (DHX), and scientists should focus more on this important…
A small biotech spinout from Johns Hopkins has published its data from a midstage study of a new Alzheimer’s drug that it’s planning to get into a late-stage study. And AgeneBio, founded by Johns Hopkins investigator Michela Gallagher, says the numbers back up its case that they may have something that works against the memory-robbing…
A clinical trial testing a current drug to treat epilepsy shows the drug can delay development of Alzheimer’s disease in its earliest stages. Results of the study, conducted by researchers at Johns Hopkins University for AgeneBio Inc., two year-old pharmaceutical company in Baltimore, appear online in the journal NeuroImage: Clinical…
A novel therapeutic approach for an existing drug reverses a condition in elderly patients who are at high risk for dementia due to Alzheimer’s disease, researchers at Johns Hopkins University have discovered.
